MaxCyte (MXCT) has released an update.
MaxCyte, Inc. CEO Maher Masoud has bolstered his investment in the company by purchasing 100,000 shares using personal funds, at an average price of $4.8907 per share. Following this transaction, Masoud’s total shareholding in MaxCyte now stands at 0.1 percent of the issued share capital, alongside significant options and performance stock units. This move by the CEO reflects confidence in the cell-engineering firm, which is known for its ExPERT™ platform and is actively involved in advancing cell-based therapies and research.
For further insights into MXCT stock, check out TipRanks’ Stock Analysis page.
